Théa has agreed to purchase seven branded ophthalmic products from Akorn, according to a press release.
“We are thrilled to expand our presence in the U.S. eye care community with a portfolio of products that are widely recognized and frequently used because they make a difference in patients’ lives,” Susan Benton, general manager, head of U.S., Théa, said in the release.
The deal will add Zioptan (tafluprost ophthalmic solution), AcellFX (acellular amniotic membrane), Betimol (timolol ophthalmic solution), Cosopt (dorzolamide HCl and timolol maleate ophthalmic solution),